Biosign to demonstrate latest generation medical measurement system at International MeMeA symposium

Biosign Technologies Inc. (TSXV: BIO) ("Biosign") announced today that it will introduce its latest generation medical measurement system, the UFIT® TEN-20, at the International Symposium on Medical Measurements and Applications (MeMeA), being held in Italy by the Institute of Electrical and Electronics Engineers (IEEE) on May 30-31, 2011. Dr Radu Leca, Biosign's CEO, will speak and demonstrate the system during the Plenary Session - Invited Lecture "Issues in Medical Measurement".

Biosign's UFIT® TEN-20 is an online medical system for blood pressure and blood glucose monitoring. The device measures the pulse at the wrist through an inflatable cuff and immediately produces blood pressure and blood glucose measurement results. All measurements are indirect, noninvasive and passive. The results are stored on Biosign's servers along with the complete test sample. Readings can be viewed by care providers on a secure web portal and/or integrated into a patient's Electronic Health Record. The UFIT® TEN 20 is approved under ISO-13485 for the non-invasive measurement of blood pressure and blood glucose, and it also carries the CE Mark.

"The MeMeA conference offers us a unique opportunity to introduce our technology to professional and academic thought leaders and to gather their support for our work", stated Dr. Radu Leca, Biosign's CEO.